Scandinavian Biopharma announces positive results from its phase I study of a traveler’s diarrhea vaccine
Scandinavian Biopharma announces positive results from its phase I study of a traveler’s diarrhea vaccine.The results are very encouraging. The vaccine was shown to be safe and elicited an intestinal immune response to the vaccine components. A new clinical phase-I study to document the safety and immunogenicity of the final composition vaccine has been initiated.